---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-023988"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2025-02-11T23:59:59+00:00"
generated_at: "2026-05-26T23:28:50.108235+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma Q4 2024: Royalty Receipts +12% to $729M; 2025 guidance $2.9B–$3.05B

## Summary
- Portfolio Receipts $742M in Q4 (+1% YoY); FY 2024 $2,801M (-8% due to $525M Biohaven milestones in 2023).
- Net cash from operations $743M in Q4, $2,769M for FY. Adjusted EBITDA $669M (Q4), $2,565M (FY).
- 2025 Portfolio Receipts guidance $2,900M–$3,050M (+4–9% growth), excluding future transactions.
- Capital deployed $2.8B in 2024; new $3B share repurchase program authorized in Jan 2025, $2B planned in 2025.
- Acquisition of external manager RP Management for ~$1.1B in equity/cash/debt; expected Q2 2025 close.

## SEC filing metadata
- accession: 0001193125-25-023988
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2025-02-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000119312525023988/0001193125-25-023988-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000119312525023988/d929959d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-023988
- JSON: https://secwatch.observer/filing/0001193125-25-023988.json
- Plain text: https://secwatch.observer/filing/0001193125-25-023988.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.